The company remains entirely pre-revenue, with core profitability metrics obscured by non-operating interest income that masks the $456.5K quarterly administrative expense burden.
| Sales/Revenue | 0 | - | - |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | - | - |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 1.26M | 1.2M | 704 |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 1.26M | 1.2M | 704 |
| SG&A % of Revenue | - | - | - |
| Research & Development | 0 | - | - |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 0 | - | - |
| Operating Income | -1.26M | -1.2M | -703 |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -169983.5% | - |
| EBITDA | -1.26M | -1.2M | 1 |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | -99999900% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 704 |
| EBIT | -1.26M | -1.2M | -703 |
| Net Interest Income | 7.78M | 8.48M | 1.59M |
| Interest Income | 7.78M | 8.48M | 1.59M |
| Interest Expense | 0 | 0 | 0 |
| Other Income/Expense | 0 | - | - |
| Pretax Income | 6.62M | 7.29M | 2.66K |
| Pretax Margin % | - | - | - |
| Income Tax | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% |
| Net Income | 6.62M | 7.29M | 2.66K |
| Net Margin % | - | - | - |
| Net Income Growth % | - | 273607.25% | - |
| Net Income (Continuing) | 6.62M | 7.29M | 2.66K |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | 0.34 | 0.30 | 0.05 |
| EPS Growth % | - | 453.51% | - |
| EPS (Basic) | - | 0.30 | 0.05 |
| Diluted Shares Outstanding | 19.2M | 19.2M | 24.58M |
| Basic Shares Outstanding | 19.2M | 19.2M | 24.58M |
| Dividend Payout Ratio | - | - | - |
Liquidation deadline execution risk
As reported in recent financial filings, OACC's quarterly SG&A expenses have trended upward to $456.5K in 2026Q1, reflecting the mounting costs of maintaining public listing status and conducting due diligence as the company approaches its eventual business combination deadline within the competitive life sciences shell sector.
The steady rise in administrative outflows suggests that the company is intensifying its search for a suitable target, which necessitates higher professional and legal fees. Investors should monitor whether this expense trajectory remains sustainable relative to the remaining cash reserves, as these fixed costs provide no operational revenue offset.
Based on the provided income statement data, OACC's reported net income of $1.4M in 2026Q1 is entirely decoupled from core operations, as the entity generates no revenue and relies on interest income from trust account holdings to offset its ongoing administrative and professional service expenditures.
The positive net income figures observed in recent quarters appear to be a function of interest rate environments rather than business performance. Analysts should strip out these non-operating gains to evaluate the true cash burn rate, which is the more accurate metric for assessing the company's remaining runway.
While OACC maintains a cash position of $1,434,965, the persistent quarterly operating losses, which reached $456.5K in 2026Q1, suggest that the company's ability to fund its search for a target is finite and may force management into a suboptimal transaction to avoid liquidation.
The market may be overestimating the sponsor's ability to wait for the perfect distressed asset. If the search window narrows without a viable target, the pressure to deploy capital may lead to a business combination that lacks the fundamental quality required for long-term shareholder value creation.
According to the historical income statement, OACC exhibits no operating leverage, as the company has yet to generate revenue, resulting in a consistent operating loss that scales directly with the administrative requirements of maintaining a public shell entity in the current regulatory environment.
The absence of revenue means that every dollar spent on SG&A directly impacts the net asset value of the trust. Until a business combination is finalized, the company will continue to operate with a negative margin profile, making traditional operating leverage analysis inapplicable to its current lifecycle stage.
Quick answers to the most common questions about buying OACC stock.
Oaktree Acquisition Corp. III Life Sciences (OACC) is profitable, generating $7.3M in net income for the fiscal year ending 2025.